Modified MBNL Polypeptide for Myotonic Dystrophy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myotonic dystrophy, such as modified oligonucleotide antisense approaches, are inefficient in reversing splicing misregulations and counteracting clinical symptoms like myotonia, highlighting the need for alternative methods to address the RNA toxicity caused by expanded CUG repeats.
Innovation Solution
A modified MBNL polypeptide with reduced splicing activity is used, expressed via viral vectors, to bind pathological CUG repeats and release sequestered endogenous MBNL proteins, thereby restoring their function and correcting splicing defects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modified oligonucleotide antisense approaches are used to interfere with CUGexp-RNAs, then MBNL1 sequestration is reduced, but splicing misregulation reversal is inefficient
Solution Approach 1:
The patent introduces a modified MBNL polypeptide as an intermediary substance that binds to CUGexp-RNAs with high affinity. This modified polypeptide acts as a mediator to displace sequestered MBNL1 from pathological RNA aggregates, thereby restoring normal splicing function without directly interfering with the CUGexp-RNAs themselves. The modified MBNL polypeptide serves as a bridge between the pathological RNA and the therapeutic goal of restoring MBNL1 function.
Solution Approach 2:
The patent employs parameter changes by modifying the MBNL polypeptide structure to alter its binding properties. Specifically, the modified MBNL polypeptide has enhanced affinity for CUGexp-RNAs compared to endogenous MBNL1, while maintaining the ability to bind and release MBNL1 from aggregates. This parameter change in binding affinity enables more effective displacement of sequestered MBNL1 and reversal of splicing misregulation.
2Reliability
If MBNL1 is sequestered in ribonucleoprotein complexes by CUG repeats, then RNA toxicity is caused, but loss of splicing function occurs
Solution Approach 1:
The patent converts the harmful sequestration mechanism into a beneficial therapeutic approach. By introducing a modified MBNL polypeptide that binds even more strongly to CUGexp-RNAs, the therapy exploits the same sequestration mechanism to displace endogenous MBNL1 from pathological aggregates. The modified polypeptide acts as a decoy that binds to the toxic RNA, thereby releasing functional MBNL1 and converting the harmful RNA-protein interaction into a therapeutic tool.
Solution Approach 2:
The modified MBNL polypeptide serves as an intermediary that mediates the displacement of endogenous MBNL1 from CUGexp-RNA aggregates. It binds to the pathological RNA with high affinity, forming a temporary complex that facilitates the release of sequestered MBNL1, thereby restoring normal splicing function without directly targeting the RNA for degradation.
3Reliability
If splicing activity is reduced in the modified MBNL polypeptide, then endogenous MBNL function is preserved, but direct splicing correction is limited
Solution Approach 1:
The modified MBNL polypeptide with reduced splicing activity enables self-service by allowing endogenous MBNL1 to perform the splicing correction function. Instead of the modified polypeptide directly correcting splicing defects, it facilitates the release and restoration of endogenous MBNL1, which then resumes its normal splicing regulatory functions. This self-service approach ensures that the native splicing machinery is preserved and utilized.
Solution Approach 2:
The modified MBNL polypeptide acts as an intermediary that facilitates the restoration of endogenous MBNL1 function without directly performing splicing correction. It binds to CUGexp-RNAs, displaces sequestered MBNL1, and enables the endogenous protein to resume its splicing regulatory activities, thereby indirectly correcting splicing defects through restoration rather than direct intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified MBNL polypeptide effectively counteracts CUGexp-RNA toxicity, normalizing splicing events and alleviating myotonia in both in vitro and in vivo models, providing a novel therapeutic approach for myotonic dystrophy.
Implementation Method 1
MBNL1 like the other MBNL protein paralogues binds to expanded CUG repeats with high affinity, and colocalizes with nuclear foci of CUGexp-RNA in DM1 muscle cells
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to compositions and methods for treating myotonic dystrophy.